Edition:
United States

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

56.24USD
15 Dec 2017
Change (% chg)

$0.23 (+0.41%)
Prev Close
$56.01
Open
$56.22
Day's High
$56.36
Day's Low
$55.75
Volume
11,873,623
Avg. Vol
3,350,796
52-wk High
$66.80
52-wk Low
$53.63

Latest Key Developments (Source: Significant Developments)

Merck Provides Update On Keynote-061, A Phase 3 Study Of Keytruda (Pembrolizumab)
Thursday, 14 Dec 2017 04:45pm EST 

Dec 14 (Reuters) - Merck & Co Inc ::MERCK PROVIDES UPDATE ON KEYNOTE-061, A PHASE 3 STUDY OF KEYTRUDA® (PEMBROLIZUMAB) IN PREVIOUSLY TREATED PATIENTS WITH GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA.MERCK PROVIDES UPDATE ON KEYNOTE-061, A PHASE 3 STUDY OF KEYTRUDA® (PEMBROLIZUMAB) IN PREVIOUSLY TREATED PATIENTS WITH GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA.MERCK & CO INC - PIVOTAL PHASE 3 KEYNOTE-061 TRIAL DID NOT MEET ITS PRIMARY ENDPOINT.MERCK & CO INC - CONTINUE TO EVALUATE KEYTRUDA FOR GASTRIC OR GEJ ADENOCARCINOMA THROUGH KEYNOTE-062.MERCK - CONTINUE TO EVALUATE KEYTRUDA FOR GASTRIC OR GEJ ADENOCARCINOMA THROUGH KEYNOTE-062.MERCK - ALSO CONTINUE TO EVALUATE KEYTRUDA FOR GASTRIC OR GEJ ADENOCARCINOMA WITH KEYNOTE-585.MERCK - PROGRESSION FREE SURVIVAL IN PD-L1 POSITIVE POPULATION DID NOT SHOW STATISTICAL SIGNIFICANCE IN KEYNOTE-061.MERCK & CO INC - NO NEW SAFETY SIGNALS WERE IDENTIFIED IN KEYNOTE-061.  Full Article

Merck Says Prevymis To Be Available In Canada By End Of December
Thursday, 14 Dec 2017 01:20pm EST 

Dec 14 (Reuters) - Merck & Co Inc ::MERCK & CO SAYS RECENTLY APPROVED PREVYMIS (LETERMOVIR) IS EXPECTED TO BE AVAILABLE IN CANADA BY END OF DECEMBER 2017.  Full Article

Newlink Genetics, Bps And Merck Sharp & Dohme Amended License & Collaboration Agreement
Monday, 11 Dec 2017 05:35pm EST 

Dec 11 (Reuters) - Merck & Co Inc ::NEWLINK GENETICS - ON DEC 5, BPS AND MERCK SHARP & DOHME CORP AMENDED LICENSE & COLLABORATION AGREEMENT DATED NOV 21, 2014.NEWLINK GENETICS-UNDER MERCK AMENDMENT, MODIFIED MERCK'S SUBLICENSE OF IP RIGHTS UNDER PHAC LICENSE AGREEMENT TO BE NON-EXCLUSIVE ON EBOLA SUDAN FIELD OF USE.NEWLINK GENETICS - AMENDMENT ALSO ADJUSTS EXPIRATION OF MERCK'S OBLIGATION TO PAY ROYALTIES TO BPS BASED ON ROYALTY TERM OF PHAC LICENSE AGREEMENT.  Full Article

Neon Therapeutics To Collaborate with Merk on Clinical Trial
Thursday, 7 Dec 2017 07:00am EST 

Dec 7 (Reuters) - Merck & Co Inc ::NEON THERAPEUTICS ANNOUNCES CLINICAL TRIAL COLLABORATION WITH MERCK.NEON THERAPEUTICS - ENTERED CLINICAL TRIAL COLLABORATION WITH MERCK TO EVALUATE CO'S NEOANTIGEN VACCINE, NEO-PV-01, IN COMBINATION WITH MERCK'S KEYTRUDA.NEON THERAPEUTICS SAYS COLLABORATION AGREEMENT IS BETWEEN CO AND MERCK, THROUGH A SUBSIDIARY; ADDITIONAL DETAILS WERE NOT DISCLOSED..NEON THERAPEUTICS - CO, MERCK TO WORK ON PHASE 1B TRIAL EXAMINING SAFETY, PRELIMINARY EFFICACY OF NEO-PV-01 COMBINED WITH KEYTRUDA, AMONG OTHERS.  Full Article

Merck's Mavenclad (Cladribine Tablets) Approved For Relapsing-Remitting Multiple Sclerosis In Canada
Monday, 4 Dec 2017 03:09am EST 

Merck & Co Inc ::MERCK'S MAVENCLAD (CLADRIBINE TABLETS) APPROVED FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS IN CANADA.  Full Article

Merck Announces $10 Billion Share Repurchase Authorization
Tuesday, 28 Nov 2017 02:33pm EST 

Nov 28 (Reuters) - Merck & Co Inc ::MERCK ANNOUNCES INCREASED QUARTERLY DIVIDEND AND $10 BILLION SHARE REPURCHASE AUTHORIZATION.MERCK & CO INC - AUTHORIZED AN ADDITIONAL $10 BILLION OF TREASURY STOCK PURCHASES WITH NO TIME LIMIT FOR COMPLETION​.MERCK - INCREASED CO'S QTRLY DIVIDEND TO $0.48/OUTSTANDING SHARE OF CO'S COMMON STOCK, UP $0.01 FROM $0.47 PER OUTSTANDING SHARE PAID LAST QUARTER.  Full Article

Cue Biopharma announces collaboration with Merck
Thursday, 16 Nov 2017 08:00am EST 

Nov 16 (Reuters) - Cue Biopharma:‍Cue Biopharma says a strategic research collaboration and license agreement with Merck.Cue Biologics platform will be leveraged to develop biologics engineered to selectively modulate disease-relevant T cell subsets​.Says specific financial arrangements are not being disclosed​.Says will receive an up-front payment​.Eligible to earn up to $374 million in research, regulatory & commercial milestone payments in addition to tiered royalties on sales​.  Full Article

Merck reports 6.5 pct passive stake in Spero Therapeutics as of Nov 6
Wednesday, 15 Nov 2017 04:52pm EST 

Nov 15 (Reuters) - Merck & Co Inc :Merck & Co reports 6.5 percent passive stake in Spero Therapeutics Inc as of Nov 6 - SEC Filing​.  Full Article

Merck reports final results of any and all tender offers
Tuesday, 14 Nov 2017 06:55am EST 

Nov 14 (Reuters) - Merck & Co Inc ::Merck announces final results of any and all tender offers.Merck & Co Inc - ‍offers expired at 5:00 p.m., New York City time, on Nov. 13, 2017​.Merck - amount of notes tendered & accepted for purchase was about $584.7 million, exclusive of notes tendered pursuant to guaranteed delivery procedures​.  Full Article

Merck announces pricing of any and all tender offers
Monday, 13 Nov 2017 02:00pm EST 

Nov 13 (Reuters) - Merck & Co Inc ::Merck announces pricing of any and all tender offers.Says ‍as of date of offers, aggregate outstanding principal amount of notes was about $2.95 billion​.Says ‍offers are scheduled to expire at 5:00 p.m., New York City Time, on Nov.13, 2017​.  Full Article

Merck's Keytruda fails pivotal gastric cancer trial

Merck & Co Inc said on Thursday a key late-stage trial testing its blockbuster drug, Keytruda, failed to meet its main goal of extending lives of patients with a type of gastric cancer.